Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding of once-daily subcutaneous semaglutide versus placebo and liraglutide in type 2 diabetes
2014-003196-39Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started May 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003196-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003196-39.